Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
宁宁金荞麦片 (Ningning Jinqiaomai Tablets) is a traditional Chinese medicine (TCM) manufactured by Jinghua Pharmaceutical Group. The primary active ingredient is the extract of the rhizome of *Fagopyrum cymosum* (Wild Buckwheat). It is clinically indicated for clearing heat, detoxifying the body, removing pus, and resolving phlegm. It is primarily used to treat respiratory conditions, including acute and chronic bronchitis, pneumonia, and lung abscesses. The pharmacological effects are attributed to its anti-inflammatory and antibacterial properties, largely derived from its flavonoid and condensed tannin content. It is administered orally in tablet form and is approved for marketing in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 宁宁金荞麦片.